Aside from the CD19 antigen, VHH-based CAR-Ts could also be used for the simultaneous targeting of other hematologic malignancy-associated target antigens such as CD20, CD22, CD123, CD30, etc (17, 20). Here, CD19 is linked to hematologic disorder.